Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
PURPOSE: Phase II trial to study the effectiveness of allogeneic umbilical cord blood transplantation in treating patients who have leukemia, lymphoma, or nonmalignant hematologic disorders.
|Leukemia Lymphoma Myelodysplastic Syndromes Myelodysplastic-Myeloproliferative Diseases||Biological: anti-thymocyte globulin Biological: filgrastim Drug: busulfan Drug: cyclophosphamide Drug: cyclosporine Drug: fludarabine phosphate Drug: melphalan Drug: methylprednisolone Procedure: umbilical cord blood transplantation Radiation: radiation therapy||Phase 2|
|Study Design:||Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation|
|Study Start Date:||January 2003|
|Study Completion Date:||September 2005|
|Primary Completion Date:||September 2003 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00055653
Show 25 Study Locations
|Study Chair:||Philip L. McCarthy, MD||Roswell Park Cancer Institute|